---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-036938"
form_type: "8-K"
ticker: "GALT"
cik: "0001133416"
company_name: "GALECTIN THERAPEUTICS INC"
filed_at: "2024-08-13T23:59:59+00:00"
generated_at: "2026-05-31T09:36:01.998841+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Galectin Therapeutics reports Q2 2024 net loss of $12.4M; NAVIGATE interim readout on track for Dec 2024

## Summary
- NAVIGATE Phase 2b/3 trial of belapectin on track for interim top-line analysis in December 2024.
- Cash and equivalents of $25.6M at June 30, 2024; $10M line of credit from chairman available.
- Net loss for Q2 2024 was $12.4M ($0.20 per share) vs $9.2M ($0.15 per share) in Q2 2023.
- R&D expenses rose to $9.8M from $7.4M, driven by NAVIGATE trial costs.
- Cash runway expected to fund operations through approximately May 15, 2025.

## SEC filing metadata
- accession: 0001140361-24-036938
- form_type: 8-K
- ticker: GALT
- cik: 0001133416
- company_name: GALECTIN THERAPEUTICS INC
- filed_at: 2024-08-13T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1133416/000114036124036938/0001140361-24-036938-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1133416/000114036124036938/ef20033852_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-036938
- JSON: https://secwatch.observer/filing/0001140361-24-036938.json
- Plain text: https://secwatch.observer/filing/0001140361-24-036938.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.